Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China.
Hong Y, Song M, Lan Y, Wang J, Lu S, Zhang Y, Zhu J, Sun F, Huang J, Liu J, Xu J, Wu Y, Guo H, Cai R, Zhen Z, Que Y, Zhang Y.
Hong Y, et al. Among authors: wang j.
Front Immunol. 2023 Jun 9;14:1182751. doi: 10.3389/fimmu.2023.1182751. eCollection 2023.
Front Immunol. 2023.
PMID: 37359533
Free PMC article.